Home World News Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with... World News Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 951 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Clinical Trials in Genitourinary Cancers: TALAPRO-2, KEYNOTE-905, and COSMIC-313 July 9, 2020 Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 July 6, 2026 EMA Recommends Granting a Conditional Marketing Authorisation for Selumetinib April 30, 2021 Happy Occupational Therapy Month April 19, 2023 Load more HOT NEWS High Risk of BCSM at 20 Years in Men with Hormone... No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with... EMA Recommends Granting a Marketing Authorisation for Generic Sorafenib Elderly Woman Seeks Trick-Or-Treaters Who Surprised Her With Gifts The Day...
